Our team

Ken Romeril MNZM, MBChB, FRACP, FRCPA

Chief Executive & Trustee

Ken is a clinical haematologist with long experience in treating malignant blood disorders. After training at Otago, in Sydney and Southhampton, in the UK, he worked at the Blood and Cancer Centre at Wellington Hospital for 26 years until 2016. Over recent years he has focused on multiple myeloma and helped establish Wellington Hospital as New Zealand’s leading centre, with specialized myeloma clinics and a major centre for clinical trials. The author of 27 publications in peer reviewed journals, Ken is a member of the American Society of Haematology (ASH) and the European Hematology Association (EHA).

Ken is a past chair of the Myeloma section of the based in Melbourne-based Australasian Leukemia & Lymphoma Group (ALLG), which is the principal trial organization for blood cancers.

Currently Ken is consulting at Wakefield Hospital and the new Bowen Icon Cancer Centre, and is the New Zealand representative on the International Myeloma Working Group, a body of 160 myeloma physicians who meet regularly and publish state-of-the-art journal articles.

He is also currently one of two New Zealand representatives on the Medical Advisory Group for Myeloma Australia which puts out Myeloma Treatment Guidelines.

In the New Year Honors 2022, Ken was awarded the the New Zealand Order of Merit for services to haemotology.

Barbara Horne

Trustee

Barbara has had an extensive career in leadership, operational and customer-facing roles in the motor industry and in banking.  She is currently Head of Conduct and Customer Inclusion at BNZ.  Her strong track record in understanding the fundamentals that enable organisations to thrive has been invaluable in helping Myeloma New Zealand move towards achieving its vision.

Barbara’s involvement with myeloma began with her husband’s diagnosis in 2015, leading her to develop a deep understanding of the disease, the treatment pathways, and the huge challenges faced by patients and their families. 

Dr Henry Chan

Trustee

Dr Henry Chan BHB, MBChB, FRACP, FRCPA is a New Zealand-trained haematologist with expertise in multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

After completing his advanced training in clinical and laboratory haematology, Henry undertook a clinical fellowship at the internationally-renowned Princess Margaret Cancer Centre in Toronto, Canada. Following his return to New Zealand, he has been involved in multiple international and local collaborative research trials. As the recipient of the Rotary Ross Craig Oncology Award, Henry is currently conducting research on myeloma genomics at the University of Auckland. He also serves as honorary senior lecturer at the University, an alternate member of the Australasian Myeloma Scientific Advisory Group, and a member of the Ministry of Health Tumour Streams. Henry has so far co-authored over 20 publications and abstracts.

Joy Wilkie

Trustee

Joy Wilkie, Ngati Tarawhai and Ngai Te Rangi from her mother, Pakeha from her father, was diagnosed with multi-focal plasmacytoma in 2015, at the age of 59. She has amazing support from her son Jack, and her daughter Te Moana, who at 21 gave up a year of her life to care for her mother through chemotherapy and her stem cell transplant. Remission is fantastic for Joy and her children.

Joy is committed to advocating for myeloma patients, for the best possible care and treatment in NZ, as in comparable countries, and to supporting our haematologists who are striving so hard to progress multiple myeloma from an incurable disease to a chronic one.

Nichola Oakenfull

Trustee

Nichola has been living with multiple myeloma since mid-2020 when she was diagnosed at 41.

Nichola has worked in Industrial/Employment Relations and HR for over 20 years, in the private and public sectors in New Zealand and the UK. She also worked in Japan for two years. Nichola has a son who was six years old when she was diagnosed with myeloma. Nichola and her husband have a residential building company in Wellington.

Myeloma treatments are improving all the time and Nichola is optimistic that one day a cure will be found. However, New Zealand does not fund many of the modern treatments and testing available overseas. One of the reasons Nichola was keen to become involved with Myeloma New Zealand is to advocate for these to be government funded. Nichola also wants to help improve the life of those living with myeloma and their loved ones, by way of information and education, and other appropriate supports. 

Melanie Murray 

Executive Assistant

Working in supporting roles for organisations that improve quality of life for people is what Melanie is passionate about. Initially trained as a Veterinary Nurse, this took her over to the U.K. to work in a Veterinary referral orthopaedic surgery.

Since returning to New Zealand, Melanie has developed a love for the not-for-profit and charitable sector by working for the Red Cross and Plunket, as well as private medical clinics specialising in Psychotherapy and Immigration. Melanie currently also works for a membership organisation in a support capacity managing events. 

She has an interest in health and well-being and is enthusiastic about supporting Myeloma patients and their wider whanau in New Zealand. Melanie enjoys spending time with her family, bush walking, SPCA Fostering and cycling on her E-Bike around the Kapiti cycle trails.

Tania Crosbie

Special Projects Manager

Tania works as an independent consultant undertaking projects requiring evidence based writing, including work involving innovative treatments for blood cancers. Prior to this she spent 15 years working in the Pharmaceutical industry in various business and leadership roles.

In 2014 Tania’s husband Paul was diagnosed with myeloma, leading her to gain insights as a carer and provide support in helping Paul and their family understand and navigate the health system. Paul is currently in remission and they are both grateful for the expertise and compassion of the medical experts involved in Paul’s care and hope myeloma patients will have a future with more and improved options for treatment.